Teva questions safety of MS drug from rival Biogen

(Reuters) - Teva Pharmaceutical Industries Ltd, which makes the market-leading multiple sclerosis drug Copaxone, has filed a petition with the U.S. Food and Drug Administration that could, if granted, delay entry to the market of a rival drug developed by Biogen Idec Inc.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news